Doctors in India have been instructed to refrain from attending meetings or conferences sponsored by companies that violate the Infant Milk Substitutes (IMS) Act. The IMS Act regulates the marketing of baby formula and other infant milk substitutes to promote breastfeeding. The directive comes in light of concerns about the unethical marketing practices of some companies that can undermine breastfeeding and infant health. The Indian government is urging healthcare professionals to uphold their ethical responsibilities and prioritize the well-being of infants by avoiding interactions with companies that violate the IMS Act. This move aims to protect the health of newborns and support breastfeeding as the optimal way to nourish infants. By adhering to these guidelines, doctors can contribute to promoting a culture of breastfeeding and ensuring that infants receive the best possible nutrition. It is crucial for healthcare providers to be aware of the implications of their associations with companies that do not comply with regulations aimed at safeguarding infant health. The IMS Act plays a vital role in protecting infants from potentially harmful marketing practices and promoting their overall well-being. Doctors play a key role in promoting infant health and development, and their adherence to ethical guidelines is essential in upholding the integrity of healthcare practices in India.